share_log

BRIEF-Humanigen Announces Positive Results From Phase 1 Study Of Ifabotuzumab In Glioblastoma Multiforme

BRIEF-Humanigen Announces Positive Results From Phase 1 Study Of Ifabotuzumab In Glioblastoma Multiforme

Brief-Humanigen宣佈Ifaotuzumab治療多形性膠質母細胞瘤的第一階段研究取得積極結果
路透社 ·  2021/04/09 19:04

April 9 (Reuters) - Humanigen Inc :
   * HUMANIGEN ANNOUNCES POSITIVE RESULTS FROM PHASE 1 STUDY OF IFABOTUZUMAB IN GLIOBLASTOMA MULTIFORME
   * HUMANIGEN INC - PHASE 1 DOSE ESCALATION AND BIOIMAGING STUDY SHOWS THAT IFABOTUZUMAB DEMONSTRATES HIGHLY SPECIFIC TUMOR TARGETING IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)

路透4月9日電-Humanigen Inc：*HUMANIGEN宣佈IFABOTUZUMAB治療多形性膠質母細胞瘤的第一階段研究取得積極結果*HUMANIGEN INC-1期劑量遞增和生物成像研究表明，IFABOTUZUMAB在複發性多形性膠質母細胞瘤患者中顯示出高度特異性的腫瘤靶向性Eikon的源文本：進一步的公司報道：(Reurs.Briefs@thomsonreurs.com；)

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論